Treatment With Full-spectrum Cannabis Extract of Refractory Epilepsy Associated With Tuberous Sclerosis Complex (TSC)
Recruiting now · Phase 3 · Has a placebo group
Conditions studied: Tuberous Sclerosis Complex (TSC)
In brief
1\. To assess treatment efficacy with YCJ-01 by changes in the number of epileptic seizures in patients with refractory epilepsy secondary to Tuberous Sclerosis Complex. 2. To assess the safety of the treatment with YCJ-01 in patients with refractory epilepsy secondary to Tuberous Sclerosis Complex.
Key facts
- Study ID
- NCT07403266
- Run by
- Oils4Cure
- People needed
- 84
- Starts
- 2024-06-01
- Expected to finish
- 2027-06-01
- Last updated by the study team
- 2026-02-11
Who can join
Age: 2 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Hospital Ruber Internacional — Madrid, Spain (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.